Article Text

other Versions

  • You are currently viewing an earlier version of this article (August 05, 2008).

PDF

Antibiotic treatment is associated with reduced risk of a subsequent exacerbation in obstructive lung disease: A historical population-based cohort study
  1. Berendina M Roede (i.roede{at}amc.uva.nl)
  1. Academic Medical Center - University of Amsterdam, Netherlands
    1. Paul Bresser (p.bresser{at}amc.uva.nl)
    1. Academic Medical Center, University of Amsterdam, Netherlands
      1. Patrick Bindels (p.j.bindels{at}amc.uva.nl)
      1. Academic Medical Center, University of Amsterdam, Netherlands
        1. Annemieke Kok (ankok{at}ggd.amsterdam.nl)
        1. Municipal Health Service, Cluster Infectious Diseases, Amsterdam, Netherlands
          1. Maria Prins (mprins{at}ggd.amsterdam.nl)
          1. Municipal Health Service, Cluster Infectious Diseases, Amsterdam, Netherlands
            1. Gerben ter Riet (g.terriet{at}amc.uva.nl)
            1. Academic Medical Center, University of Amsterdam, Netherlands
              1. Ronald Geskus (r.b.geskus{at}amc.uva.nl)
              1. Academic Medical Center, University of Amsterdam, Netherlands
                1. Ron Herings (ron.herings{at}pharmo.nl)
                1. Pharmo Institute Utrecht, Netherlands
                  1. Jan Prins (j.m.prins{at}amc.uva.nl)
                  1. Academic Medical Center, University of Amsterdam, Netherlands

                    Abstract

                    Objectives: We evaluated the risk of a subsequent exacerbation after treatment of an exacerbation with oral corticosteroids without (OS) or with antibiotics (OSA), in a historical population-based cohort study comprising patients using maintenance medication for obstructive lung disease.

                    Methods: The Pharmo database includes drug-dispensing records of more than 2 million subjects in the Netherlands. Eligible were patients ≥ 50 years who in 2003 were dispensed ≥ 2 prescriptions of daily used inhaled β2-agonists, anticholinergics, and/or corticosteroids, and experienced at least one exacerbation before 1 January 2006. Exacerbation was defined as a prescription of OS or OSA. We compared the times to the second and third exacerbations using Kaplan-Meier survival analysis. Independent determinants of new exacerbations were identified using multivariable Cox recurrent event survival analysis.

                    Results: Of 49,599 patients using maintenance medication, 18,928 patients had at least one exacerbation; in 52% antibiotics had been added. OS and OSA groups were comparable for potential confounding factors. The median time to the second exacerbation was 321 days in the OS group and 418 days in the OSA group (p< 0.001); and between the second and third exacerbation 127 vs. 240 days (p<0.001). The protective effect of OSA was most pronounced during the first three months following treatment (hazard ratio 0.62; 99%CI 0.60 - 0.65). In the OSA group mortality during follow-up was lower (HR 0.82; 99% CI 0.66-0.98).

                    Conclusion: Treatment with antibiotics in addition to oral corticosteroids was associated with a longer time to the next exacerbation, and a decreased risk of developing a new exacerbation.

                    Statistics from Altmetric.com

                    Request permissions

                    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

                    Linked Articles